MENU
Alnylam Act

Alnylam Act

Alnylam is sponsoring free, third-party genetic testing and counseling for individuals who may carry a gene mutation known to be associated with hereditary ATTR (hATTR) amyloidosis. The Alnylam Act™ (formerly known as Alnylam Assist) program was created to potentially increase diagnosis rates and to provide genetic counseling to help people make more informed decisions about their health. Learn More.

Measurement Properties of the Rasch-built Overall Disability Scale (R-ODS) in patients with hATTR Amyloidosis with Polyneuropathy

Measurement Properties of the Rasch-built Overall Disability Scale (R-ODS) in patients with hATTR Amyloidosis with Polyneuropathy

We presented data evaluating the measurement properties of the Rasch-built Overall Disability Scale (R-ODS) in patients with symptomatic hereditary ATTR (hATTR) amyloidosis with polyneuropathy.  R-ODS is a 24-item patient-reported outcome instrument that assesses activity and social participation limitation. R-ODS assessments were collected from two trials investigating patisiran.  These data were presented at the International Society for Pharmacoeconomics and Outcomes Research annual meeting in Boston, Massachusetts.


Read More

Final 24-Month Results from Phase 2 OLE Study of Patisiran, in Development for hATTR Amyloidosis

Final 24-Month Results from Phase 2 OLE Study of Patisiran, in Development for hATTR Amyloidosis

We reported final 24-month results from our Phase 2 open-label extension (OLE) study of patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR (hATTR) amyloidosis. These data were presented at the American Academy of Neurology (AAN) 2017 Annual Meeting in Boston, Massachusetts.



Read More

Alnylam RNAi

RNAi, a Promising Potential New Class of Medicines

RNAi has the potential to change the landscape of medicine as we know it—but how does it work, exactly? Watch the video below to learn how this mechanism has the ability to harness a natural pathway and target virtually any protein involved in the cause of disease.


From Possibility to Patients

From Possibility to Patients

In 2006, Craig Mello, Ph.D., and Andrew Fire, Ph.D., received the Nobel Prize for Medicine for the discovery of RNA Interference (RNAi). Alnylam is recognizing the 10th anniversary of this historic achievement and the progress made toward delivering RNAi therapeutics, an entirely new class of innovative medicines to patients. Explore this page to learn more about our story and the scientific journey of RNAi—from possibility, to potential treatment for patients.


Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual Helping Hands Community Service Day

Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping Hands" Community Service Day

On June 23, over 400 Alnylam employees participated in its second annual company-wide “Helping Hands” Community Service Day to benefit ten local non-profit organizations including: Boston Nature Center, Cradles to Crayons, Emerald Necklace Conservancy, Friends of Alewife, Habitat Education Center, IMEC America, Cupboard of Kindness, Norton Conservation Land, West End House Boys and Girls Club and Windrush Farms.


Behind the Mystery: Rare + Genetic Series - TTR Amyloid

Behind the Mystery: Rare & Genetic Series - TTR Amyloid

Battling a rare medical condition, that's often misdiagnosed.
Imagine having a rare, debilitating disease that's passed down through families. Dr. John Berk, Associate Professor of Medicine at Boston University and Clinical Director of its Amyloidosis Center, joins us to discuss the medical condition called Transthyretin-Mediated Amyloidosis. It's symptoms are similar to other conditions and ATTR patients are very often misdiagnosed. We discuss symptoms, family connections and treatment options, in this Behind the Mystery: Rare & Genetic segment. And meet Dylan Duncan, who's battling the disease. You don't want to miss this.